Informed Consent to Psychedelic-Assisted Psychotherapy: Ethical Considerations
The Canadian Journal of Psychiatry January 17, 2024 Andrew G. Lee, Daniel Rosenbaum, Daniel Z. Buchman 25 citations
No Summary
Daniel Z. Buchman
7 papers in the library · 63 citations · publishing 2023-2025
Papers
Ethical Considerations at the Intersection Between Psychedelic-Assisted Psychotherapy and Medical Assistance in Dying
AJOB Neuroscience April 3, 2023 Daniel Rosenbaum, Matthew Cho, Evan Schneider et al. 11 citations
No Summary
Experiential Training in Psychedelic-Assisted Therapy: A Risk-Benefit Analysis.
Hastings Cent Rep July 1, 2024 Daniel Rosenbaum, Crystal Hare, Emma Hapke et al. 10 citations
Experiential training—where aspiring therapists undergo psychedelic-assisted therapy themselves—should not be mandatory, according to an ethical analysis applying Sandell et al.'s framework of training therapy functions. The analysis identifies five potential benefits (therapeutic, modeling, empathic, persuasive, and theoretical functions) but weighs them against six domains of risk: physical and psychological harms, negative effects on therapeutic skill, justice and equity concerns, dual relationships, privacy breaches, and undue pressure. Because many programs already include experiential components, the authors argue that the analysis can inform risk-mitigation strategies rather than justify a requirement.
Psychedelics in PERIL: The Commercial Determinants of Health, Financial Entanglements and Population Health Ethics.
Public health ethics January 1, 2024 Daniel Z. Buchman, Daniel Rosenbaum 8 citations
The for-profit psychedelic industry is starting to fund scientific research, mirroring practices from tobacco, alcohol, pharmaceutical, and food industries that have created conflicts of interest and harmed population health. Researchers face limited ethics guidance on accepting such sponsorship. A group of clinician scientists applied the PERIL ethical framework to a fictional case of corporate psychedelic funding, finding that financial ties can threaten a research program's purpose, autonomy, and integrity. The commercial determinants of health framework helps understand these industry-healthcare entanglements and offers a population health ethics lens for examining and addressing risks in the nascent psychedelic sector.
Commentary: Access to Psychedelics for Psychological Suffering at the End of Life - Prioritizing Our Priorities.
Healthcare policy = Politiques de sante May 1, 2023 Daniel Rosenbaum, Sarah Hales, Daniel Z. Buchman 5 citations
Psychedelic therapies show promise for psychological suffering at the end of life, but focusing too much on them may exaggerate the current evidence and pull resources from proven programs. The more urgent policy priority is to fix inequities in access to early, high-quality palliative and psychosocial care. Any discussion of expanding psychedelic access must also center equity concerns.
Disability rights and experiential use of psychedelics in clinical research and practice.
npj Mental Health Research July 2, 2024 Maryam Golafshani, Daniel Z. Buchman, M Ishrat Husain 3 citations
A disability-rights perspective is brought to the debate about whether psychedelic-assisted psychotherapy (PAP) researchers and clinicians should have personal experience with psychedelics. The authors argue that mandating or implying such experience can perpetuate ableism, because many psychiatric conditions and medications, including common antidepressants, may prevent safe psychedelic use. The field must prioritize disability inclusion among researchers and clinicians as PAP research and practice expand.
Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy for patients with advanced cancer: protocol for a multi-method feasibility trial
Pilot and Feasibility Studies October 28, 2025 Candice Richardson, Cindy Chan, Emily Macgregor et al. 1 citation
A new therapy combining psilocybin with evidence-based psychotherapies for people with advanced cancer, called PEARL therapy, will be tested in an open-label trial with 15 participants. The study will assess whether the therapy is acceptable, feasible, and safe by tracking recruitment, retention, adherence, and serious adverse events, and by collecting self-report questionnaires and qualitative interviews. This research aims to inform policy, training, and clinical guidelines for psychedelic-assisted therapies, which may improve quality of life for those with advanced disease.